Treatment dynamics of bone ‐targeting agents among men with bone metastases from prostate cancer in the United States

ConclusionsBone‐targeting agent therapy is initiated by the majority of men living with bone metastases following a prostate cancer diagnosis; however, the timing of initiation is highly variable. Once on treatment, gaps or interruptions in therapy are common.

Source: Pharmacoepidemiology and Drug Safety - January 1, 2018 Category: Drugs & Pharmacology Authors: Anne M. Butler, Karynsa Cetin, Rohini K. Hernandez, B. Diane Reams, Robert A. Overman, Jung I. Kim, Bradford R. Hirsch, Amy P. Abernethy, Alexander Liede, M. Alan Brookhart Tags: ORIGINAL REPORT Source Type: research